6/6/2017

Hydralazine Injection

Products Affected - Description

- Hydralazine injection, Akorn, 20 mg/mL, 1 mL vial, 10 count, NDC 17478-0934-01
- Hydralazine injection, American Regent, 20 mg/mL, 1 mL vial, 25 count, NDC 00517-0901-25

Reason for the Shortage

- Akorn has hydralazine injection available.
- American Regent has hydralazine injection on shortage due to manufacturing delays. This product has not been available for several years.
- Fresenius Kabi has hydralazine injection available.
- X-Gen launched hydralazine injection in September 2015.

Available Products

- Hydralazine injection, Akorn, 20 mg/mL, 1 mL vial, 25 count, NDC 17478-0934-15
- Hydralazine injection, Fresenius Kabi, 20 mg/mL, 1 mL vial, 25 count, NDC 63323-0614-01
- Hydralazine injection, X-Gen, 20 mg/mL, 1 mL vial, 25 count, NDC 39822-0500-04

Estimated Resupply Dates

- American Regent has hydralazine 20 mg/mL 1 mL vials on back order and the company cannot estimate a release date.
- All other marketed presentations are available.

Updated

Updated June 6, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 12, 2014 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.